AbbVie Expands Immunology Pipeline with $10.9 Billion Apogee Deal

Pharmaceutical giant AbbVie Inc. (ABBV) has completed its acquisition of Apogee Therapeutics for $10.9 billion, expanding its immunology pipeline with several key programs targeting atopic dermatitis and asthma.

The deal adds zumilokibart to AbbVie's portfolio, a treatment that targets IL-13 and shows significant skin improvement among patients after 16 weeks of phase 2 testing.

AbbVie expects the Apogee acquisition to reduce adjusted diluted earnings by $0.14 per share in 2026, but believes it will begin contributing positively to earnings in 2032.